RHSC/ForoLAC-funded research has found that opportunistic oral contraceptive price hikes have led to increases of at least 10-20% in Peru, Chile, Colombia, and Uruguay. As 60% of contraceptive funding is out of pocket, the impact on individual consumers is an unwelcome reality, especially given the negative impact of COVID on household incomes. Four partner organisations – PROMSEX Perú, Oriéntame Colombia, MYSU Uruguay and Corporación MILES de Chile – have designed an advocacy campaign to hold manufacturers accountable for excessive increases in these four countries. You can support the campaign on Twitter by following and engaging with the #ItsAboutSupplies hashtag. To read more about the reasearch and results, please download the following briefs (in Spanish):
- Chile: Investigación sobre variación de los precios de venta de los anticonceptivos orales en farmacias durante 2020
- Colombia: Línea de Base Precio Anticonceptivos Orales
- Peru: Variación de los costos de las píldoras anticonceptivas durante la pandemia
- Uruguay: Anticoncepción en cifras – Protección sexual y reproductiva en tiempos de pandemia 2021